Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4

Benzinga · 3d ago
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.